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TO THE EDITOR
Psoriasis vulgaris is a disease character-
ized by accelerated growth and altered
differentiation of keratinocytes, but
probably triggered by cellular immune
infiltrates and associated cytokines.
There have been several attempts to
reproduce this disease in animal mod-
els, including a recent publication by
Zenz et al. (2005) that claims to
reproduce psoriasis by deleting JunB
and c-Jun from epidermal keratinocytes.
The main basis for this model is a
measured decrease of JunB in epidermal
keratinocytes of skin lesions from psor-
iasis patients. Human JunB is a compo-
nent of activator protein-1 (AP-1)
transcription factor that is localized in
the PSORS6 locus. JunB is known to
regulate keratinocyte proliferation and
differentiation and this transcription
factor has been shown to be expressed
in healthy human skin (Mehic et al.,
2005). Prior work suggests that JunB
serves to suppress proliferation of kera-
tinocytes, as JunB deletion causes epi-
dermal acanthosis in an organotypic
skin culture model (Werner and Smola,
2001).
If regulatory pathways in psoriasis
vulgaris are to be studied in animal
models, there should be a requirement
that gene manipulations in models
actually reflect changes in the human
disease. The case for decreased JunB
expression is confusing, as two prior
studies suggest increased expression of
JunB mRNA or protein in psoriasis
vulgaris lesions. One recent study
(Johansen et al., 2004) showed in-
creased expression of JunB mRNA and
protein expression in whole tissue
extracts of psoriasis lesions, whereas
another recent gene profiling study of
Japanese patients with psoriasis showed
increased JunB mRNA (Kulski et al.,
2005). However, conflicting data on
JunB expression are derived from the
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Figure 1. Gene expression analysis of JunB in psoriasis. (a) Representative gene array analysis of mRNA from psoriasis lesions (LS) and non-lesional (NL) 6 mm
punch skin biopsies. mRNA was isolated from and hybridized to individual oligonucleotide arrays containing B12,000 human genes (HG-U95A arrays), as
described in our recent study (Haider et al., 2005). The figure represents the heat map of representative unsupervised hierarchical clustering for gene expressions
of signal transducer and activator of transcription 1 (STAT1), JunB, c-Jun, chemokine ligand 27 (CCL27), keratin 16 (KRT16), small proline-rich protein 1A/B
(SPRR1A, SPRR1B), involucrin (IVL), gap junction protein (GJA1), and early growth response 1 (EGR1) with fold change differences in gene expressions in LS
versus NL and the P-values (after Benjamini and Hoechberg correction for multiplicity). Red: upregulated; green: downregulated relative gene expression.
(b) mRNAs in LS and NL from 26 patients were analyzed by real time reverse transcription-PCR measurements as described in our recent study (Haider et al.,
2005). Primer sequences were as follows: K16-forward GCGAGGATGCCCACCTTT, K16-reverse GAAGACCTCGCGGGAAGAAT, K16 probe 6FAM-CCCAGC
AAGCATCTGGCCAATCC-TAMRA (GenBank accession number AF061809). The primers and probes for JunB (assay ID Hs00357891) were designed by Applied
Biosystems (Foster City, CA, USA). All primers and probes were purchased from Applied Biosystems. Mean values of gene expression for selected genes are
shown after normalization of expressions using human acidic ribosomal protein (HARP) mRNA. mRNA was analyzed from LS and NL skin biopsies (n¼26
for each): error bars are shown; **Po0.001.
study of only small numbers of patients,
and the overall genomic profile of
Japanese psoriasis is considerably dif-
ferent from Western psoriasis (Kulski
et al., 2005).
Accordingly, we re-examined the
expression of JunB expression in paired
biopsies of uninvolved and lesional skin
taken from 26 patients who had been
untreated with therapeutic agents for at
least 4 weeks. All cases studied were of
active disease where psoriasis plaques
showed marked keratinocyte hyperpla-
sia, elongation of epidermal rete, and
strong expression of keratin 16 in
lesional skin. Acquisition of the human
tissue was approved by the Rockefeller
University’s institutional review board
and the study was conducted after
patient’s consent and according to
the Declaration of Helsinki Principles.
Eleven of these patients had paired
biopsies in which global gene expres-
sion had been measured on Affymetrix
U95A arrays. As illustrated in Figure 1,
a statistically significant increase in
JunB mRNA was detected in lesional
skin, along with statistically significant
increases in keratin 16 and signal
transducer and activator of transcription
1, which serve as previously validated
genomic indicators of active disease
(Zhou et al., 2003). The c-Jun homo-
logue was essentially unaltered in
diseased skin, whereas less expression
was measured for CCL27, a gene
expected to be suppressed in psoriasis
lesions. JunB mRNA expression was
studied further in all 26 patients using
real-time reverse transcription-PCR
analysis (Figure 1b). Keratin 16 mRNA
expression was highly upregulated in
lesional skin, serving as a control for
active disease. On average, we de-
tected a small increase in JunB expres-
sion in lesional skin, consistent with the
array-based results. The combined re-
sults suggest that JunB mRNA is not
significantly suppressed in psoriasis
lesions.
We also studied expression of JunB
protein in psoriasis lesions using im-
munohistochemistry and immunofluor-
escence microscopy with the C-11
monoclonal antibody. As shown in
Figure 2, JunB was strongly stained in
keratinocyte nuclei within the hyper-
plastic epidermis of psoriasis lesions,
but much less staining was observed in
paired, uninvolved skin biopsies. A similar
pattern of JunB expression was detected
by immunofluorescence microscopy in
lesional versus uninvolved skin (Figure 2).
In total, 11/12 cases showed increased
JunB in lesional skin (Po0.003), whereas
in one case equal staining was observed
in lesional and non-lesional skin. Hence,
increased detection of JunB protein in
psoriasis vulgaris lesions confirms the
genomic picture of an increase of JunB
in lesional skin.
One final issue requires discussion.
Johansen et al. found that in vitro AP-1
promoter binding activity was reduced
in nuclear extracts from lesional psor-
iasis skin, although the levels of
JunB protein were elevated. The clear
increase in nuclear staining of JunB in
keratinocytes within active psoriasis
lesions (Figure 2) suggests that JunB
could activate AP-1 gene transcription
in these cells. Accordingly, we also
examined a set of previously identified
AP-1-regulated genes (Angel and Sza-
bowski, 2001; Hayakawa et al., 2004)
that are likely to be expressed in
epidermal keratinocytes (Figure 1)
through Affymetrix array analysis.
Genes including keratin 16 (K16),
cornifin (SPRR1B), small proline-rich
protein 1A (SPRR1A0), involucrin
(IVL), connexin 43 (GJA1), and early
growth response 1 (EGR1) are consis-
tently upregulated in lesional skin
(Po0.01 for each, after statistical cor-
rection for multiple gene analyses).
These data strongly suggest that JunB
(AP-1) is functioning as a transcriptional
activator of disease-related genes in
psoriatic keratinocytes, and there is also
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Figure 2. Immunohistochemical and immunofluorescence analysis of JunB in lesional and non-lesional
tissue. Immunohistochemical and immunofluorescence analysis of JunB in psoriasis lesional (LS) and
non-lesional (NL) tissue sections of 12 patients with psoriasis, stained as described previously (Gottlieb
et al., 2005) with mouse anti-human monoclonal antibodies to JunB (clone C-11: Santa Cruz
Biotechnology, Santa Cruz, CA, USA). (a) For immunohistochemistry, a biotin-labeled horse anti-mouse
secondary antibody (PK6102; Vector Lab, Burlingame, CA, USA) was localized with avidin–biotin
complex and developed with chromogen 3-amino-9-ethylcarbazole (A-5754; Sigma Aldrich, St Louis,
MO, USA). (b) For immunofluorescence, LS and NL tissue sections were stained with mouse anti-human
monoclonal antibody to JunB and detected with an Alexa Fluor 568-conjugated goat antibody to mouse
IgG (A21124; Molecular Probes, Eugene, OR, USA). No staining of the epidermis was seen with a control
mouse IgG isotype antibody (not shown). Bar¼ 100 mm.
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genomic evidence that AP-1-regulated
genes in other cell types are also
significantly increased in psoriasis le-
sions (data not shown). The sum of
these data does not support the hypoth-
esis that reduced expression of JunB
drives disease pathogenesis. In fact,
effective treatment of psoriasis with
calcipotriol appears to reduce expres-
sion of JunB protein (Johansen et al.,
2004). Furthermore, we have observed
a reduction in expression of JunB
mRNA in response to cyclosporine
(unpublished observation), suggesting
that induced expression in keratino-
cytes may be part of an overall inflam-
matory response.
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TO THE EDITOR
In the September issue of this journal,
Vergilis et al. (2005) report that the
high-molecular weight-melanoma-as-
sociated antigen (HMW-MAA) also
known as the melanoma chondroitin
sulfate proteoglycan (MCSP) can be
present in the blood of healthy donors
and melanoma patients. Defining
a threshold of 1XU as elevated by
their double-sandwich ELISA assay
they found significant differences in
positivity for HMW-MAA/MCSP anti-
gen among controls and melanoma
patients (29 vs 3% positivity).
The authors propose ‘‘shedding of the
antigen by both malignant cells and
normal cells but in greater amount by
cancer cells’’ as a mechanism for its
appearance in the serum without specify-
ing possible sources of the HMW-MAA/
MCSP antigen.
Our recently published data demon-
strate circulating melanoma cells
as a potential source of the HMW-
MAA/MCSP antigen found in the serum
of melanoma patients (Figure 1). In our
prospective study, we detected HMW-
MAA/MCSP-positive cells with morpho-
logical features of tumor cells in
the blood of 43 (26%) of 164 melanoma
patients, whereas all 50 controls
were negative (Ulmer et al., 2004).
The malignant origin of the HMW-
MAA/MCSP-positive cells in our
study was demonstrated unambiguously
by single-cell comparative genomic
hybridization. As we noted a faint
positivity for the HMW-MAA/MCSP
antigen on few granulocytes, one
might speculate that these cells may
contribute to the low levels of serum
HMW-MAA/MCSP antigen measurable
in controls.
In contrast to the study published by
Vergilis et al. (2005), we found a
significant association between a posi-
tive result and the number of tumor
cells detected, respectively, and the
stage of the patient. The presence of
two or more HMW-MAA/MCSP-posi-
tive tumor cells in our study had a
negative impact on survival in patients
with metastatic disease, whereas ele-
vated levels of HMW-MAA/MCSP did
not correlate with the clinical outcome
of patients in the study reported by
Vergilis et al.
The reason for these differences
remains unclear. One might speculate
Abbreviation: HMW-MAA, high-molecular weight-melanoma-associated antigen; MCSP, melanoma
chondroitin sulfate proteoglycan
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